![]() Professionals to reduce the risk of stroke in patients with nonvalvularĮLIQUIS is an oral Factor Xa inhibitor anticoagulant. Represents a significant advance over warfarin for health care Medical Center, Durham, N.C., ARISTOTLE lead investigator. Professor of Medicine, Duke Clinical Research Institute, Duke University Managed effectively with warfarin,” said Christopher Granger, M.D., “With a population that is living longer, the prevalence of nonvalvularĪtrial fibrillation is increasing, but many patients are still not being Reason other than pathological bleeding, coverage with anotherĪnticoagulant should be strongly considered.ĮLIQUIS increases the risk of bleeding and can cause serious, If anticoagulation with ELIQUIS must be discontinued for a Increased rate of stroke was observed following discontinuation ofĮLIQUIS in clinical trials in patients with nonvalvular atrialįibrillation. Patients on ELIQUIS whoĭiscontinue treatment are at an increased risk of thrombotic events. The Full Prescribing Information for ELIQUIS includes a Boxed Warningįor patients who discontinue treatment. Who were considered unsuitable for treatment with warfarin. Versus aspirin in 5,598 patients with nonvalvular atrial fibrillation Were suitable for warfarin therapy, and AVERROES evaluated ELIQUIS Warfarin in 18,201 patients with nonvalvular atrial fibrillation who Patients with nonvalvular atrial fibrillation and at least oneĪdditional risk factor for stroke. Included two landmark Phase 3 studies - ARISTOTLE and AVERROES - in Systemic embolism in nonvalvular atrial fibrillation patients it The ELIQUIS clinical trial program is the largest completed clinicalĭevelopment program designed to evaluate risk reduction of stroke or Treatment option to patients and health care professionals.” Profile of ELIQUIS, combined with the strong legacy and complementaryĬapabilities that Pfizer and Bristol-Myers Squibb have in theĬardiovascular space, positions us well to deliver this important new Ian Read, chairman and chief executive officer, Pfizer Inc. Patients with nonvalvular atrial fibrillation in the U.S.” Vision of our alliance to introduce a new oral anticoagulant for “ELIQUIS is the result of leading scientific innovation and the shared Said Lamberto Andreotti, chief executive officer, Bristol-Myers Squibb. “The approval of ELIQUIS offers patients with nonvalvular atrialįibrillation a novel treatment option for reducing the risk of stroke,” Atrialįibrillation, the most common type of irregular heartbeat, affectsĪpproximately 5.8 million people in the U.S., and results in a five Food and Drug Administration (FDA) approvedĮLIQUIS ® (apixaban) to reduce the risk of stroke and systemicĮmbolism in patients with nonvalvular atrial fibrillation. ELIQUIS Demonstrated Superior Risk Reductions Versus Warfarin in Three Key Outcomes-Stroke and Systemic Embolism, Major Bleeding and All-Cause Mortality-for Patients with Nonvalvular Atrial Fibrillationīristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |